Morgan Stanley Downgrades Fractyl Health to Equal-Weight, Lowers Price Target to $2
Benzinga Newsdesk 9 months ago
NewsDowngradesPrice TargetAnalyst Ratings
Morgan Stanley analyst Michael Ulz downgrades Fractyl Health (NASDAQ:GUTS) from Overweight to Equal-Weight and lowers the price target from $8 to $2.
Morgan Stanley analyst Michael Ulz downgrades Fractyl Health (NASDAQ:GUTS) from Overweight to Equal-Weight and lowers the price target from $8 to $2.